Product Information
Belinostat acid is an inorganic compound that has been clinically studied for its potential use in cancer treatment. Belinostat acid is a histone deacetylase inhibitor, which means it prevents the removal of acetyl groups from histones, resulting in gene activation and increased transcription. In vitro studies have shown that belinostat acid can be used to treat cancers by inducing homologous recombination repair and inhibiting cell proliferation. Clinical trials are currently underway to examine the safety and efficacy of this drug as a treatment for solid tumors. The terminal half-life of belinostat acid is about 1 hour, with metabolites being excreted primarily through urine.
Belinostat Acid has been found to inhibit HDACs and other DNA-modifying enzymes such as HATs. It also inhibits the phosphorylation of H3K9, which may play a role in tumorigenesis.
The pharmacokinetics of Belinostat
Chemical properties
Technical inquiry about: 3D-RJB32387 Belinostat acid
If you want to request a quotation or place an order, please instead add the desired products to your cart and then request a quotation or order from the cart. It is faster, cheaper, and you will be able to benefit from the available discounts and other advantages.
